Serum 7 Alpha-hydroxy-4-cholesten-3-one and Selenohomocholyltaurine (SeHCAT) Whole Body Retention in the Assessment of Bile Acid Induced Diarrhoea
Overview
Authors
Affiliations
Objective: To assess the reliability of serum 7 alpha-hydroxy-4-cholesten-3-one (7 alpha-3ox-C) in the differential diagnosis of bile acid induced diarrhoea by comparison with 75selenohomocholyltaurine whole body retention (SeHCAT WBR).
Design: One hundred and sixty-four patients with chronic diarrhoea were investigated prospectively in two centres (Edinburgh and Sweden) by two different tests which measure bile acid loss or synthesis: the SeHCAT test which measures the 7-day SeHCAT WBR and serum 7 alpha-3ox-C which reflects the rate of bile acid synthesis.
Results: Forty-six patients had SeHCAT WBR of less than 10% (19 with ileal disease or resection, nine with idiopathic bile acid induced diarrhoea and 18 with miscellaneous causes for bile acid induced diarrhoea). All patients with ileal or idiopathic disease showed a favorable response to treatment as did 13 of the miscellaneous group. Serum 7 alpha-3ox-C was raised in all subjects with ileal disease/resection, seven patients with idiopathic disease and all subjects in the miscellaneous group who responded to treatment. Sixteen out of 118 patients with SeHCAT WBR greater than or equal to 10% had raised serum 7 alpha-3ox-C.
Conclusion: The positive predictive value of serum 7 alpha-3ox-C was 74%. The high negative predictive value (98%) of serum 7 alpha-3ox-C indicates the possible use of this test for excluding bile acid malabsorption in this population. All but two subjects who responded to treatment had raised serum 7 alpha-3ox-C concentrations. The possibility that the sensitivity of the test can be improved by repeat testing needs to be further investigated. There was a significant correlation between fractional catabolic rate (FCR) SeHCAT and serum 7 alpha-3ox-C (r = 0.63, P < 0.0001). Further data are required to validate the reference range in women over 70 years of age.
Prost J, Brunner F, Bovet C, Grob C, Berchtold C, Schlotterbeck G Clin Mass Spectrom. 2024; 3:1-6.
PMID: 39193097 PMC: 11324611. DOI: 10.1016/j.clinms.2017.02.001.
Karhus M, Sonne D, Thomasen M, Ellegaard A, Holst J, Rehfeld J Gastro Hep Adv. 2024; 1(3):299-312.
PMID: 39131668 PMC: 11307667. DOI: 10.1016/j.gastha.2021.12.007.
Merza N, Saab O, Nawras Y, Abdulhussein R, Elmoursi A, Daddoo L J Clin Med Res. 2024; 16(2-3):33-45.
PMID: 38550552 PMC: 10970039. DOI: 10.14740/jocmr5007.
Sciume G, Berti G, Lambiase C, Paglianiti I, Villanacci V, Rettura F J Clin Med. 2023; 12(18).
PMID: 37762728 PMC: 10531598. DOI: 10.3390/jcm12185787.
Pathophysiology and Clinical Management of Bile Acid Diarrhea.
Marasco G, Cremon C, Barbaro M, Falangone F, Montanari D, Capuani F J Clin Med. 2022; 11(11).
PMID: 35683489 PMC: 9180966. DOI: 10.3390/jcm11113102.